Abstract 5856: Identification and validation of Nrf2 inhibitors in esophageal squamous cell carcinoma
| Autor: | Seth J. Weir, Chorlada Paiboonrungruan, Xiaoxin Chen |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
0301 basic medicine
Cancer Research Gene knockdown Somatic cell Activator (genetics) Chemistry medicine.medical_treatment respiratory system environment and public health In vitro Targeted therapy 03 medical and health sciences 030104 developmental biology 0302 clinical medicine Oncology In vivo 030220 oncology & carcinogenesis Cancer research medicine Viability assay Cytotoxicity |
| Zdroj: | Cancer Research. 78:5856-5856 |
| ISSN: | 1538-7445 0008-5472 |
| DOI: | 10.1158/1538-7445.am2018-5856 |
| Popis: | Background: The Nrf2/Keap1 pathway is critical for human cells to respond to oxidative stress. In basal conditions the Keap1 homodimer is bound to Nrf2 in the cytoplasm. When stressed, Keap1 releases Nrf2 which translocates into the nucleus, binds the antioxidant response element, and activate antioxidative genes. Somatic mutations of Nrf2 or Keap1 gene can cause constitutive activation of this pathway, and thus results in chemoradioresistance and poor survival in patients with esophageal squamous cell carcinoma (ESCC). Our goal is to identify chemical Nrf2 inhibitors for targeted therapy of Nrf2high ESCC in the future. Methods: Possible Nrf2 inhibitors were identified using high throughput screening of 1,280 compounds in the Prestwick library, and 35,000 compounds in the Asinex library with Nqo1-EGFP H1299 cells stimulated by an Nrf2 activator (CDDO). Nrf2 activity was monitored via Incucyte by measuring the total normalized green fluorescence divided by the total normalized red fluorescence (tagged nuclear cherry marker). The red channel assessed cell viability and cytotoxicity of compounds. Inhibitors were identified if they met a threshold of >50% inhibition. Lead compounds will be further validated in vitro with KYSE 450 (Nrf2low+Keap1 knockdown) and KYSE 70 (Nrf2high) by examining their effects on expression of nuclear Nrf2 and its downstream target gene (Nqo1). These compounds will also be validated in vivo using Sox2CreER;Nrf2Ki/Ki mice. Results: We successfully established the in vitro assay with Nqo1-EGFP H1299 cells for high throughput screening of Nrf2 inhibitors. Eight lead compounds were identified from the Prestwick library and validated as Nrf2 inhibitors via a dose-response experiment (IC50 Conclusion: We have identified Nrf2 inhibitors through high-throughput screening and will test them in vitro and finally in vivo. Citation Format: Seth Weir, Xiaoxin Chen, Chorlada Paiboonrungruan. Identification and validation of Nrf2 inhibitors in esophageal squamous cell carcinoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 5856. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|